Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the reproductive safety of medication for bipolar disorder with Ob.Gyn News on March [...]
Women with bipolar disorder (BD) are at extremely high risk for postpartum psychiatric illness, including postpartum psychosis. While the American College of Obstetrics and Gynecology now recommends that all women be screened for depression [...]
Numerous studies have demonstrated that women with histories of bipolar disorder are at high risk for postpartum illness. Because of this increased risk for relapse during the postpartum period, we typically recommend that women with [...]
When we meet women for consultations regarding the use of psychotropic medications during pregnancy, we focus primarily on the impact of medications on the developing fetus and the pregnancy. However, we need also to address [...]
Women with bipolar disorder are at a higher risk for relapse during pregnancy and that the risk is even higher during the postpartum period. In addition, women with bipolar disorder are more vulnerable to postpartum [...]
We are pleased to announce the recent launch of an exciting new research initiative that is being conducted by the Massachusetts General Hospital Center for Women’s Mental Health. The Symptom Tracking in Assisted Reproductive Technologies study (START study) will focus on understanding the risk factors for depressive relapse in women undergoing infertility treatments. There has been a growing request in our clinical work to address the needs of women undergoing infertility treatments. It is our hope that such a study will provide important information on the course and risk of depression in women undergoing fertility treatment and thus inform clinical care.
Unfortunately the mood stabilizers most commonly used to treat bipolar disorder (including lithium and valproic acid) can increase the risk of certain types of birth defects or congenital malformations in children exposed to these medications during the first trimester of pregnancy. For this reason, many women with bipolar disorder choose to discontinue maintenance treatment during pregnancy. However, we have observed very high rates of illness during pregnancy among these women who discontinue treatment; over half of the women relapse, most frequently during the first trimester.
